Results 91 to 100 of about 823,307 (385)

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Cancer Discovery, 2015
UNLABELLED The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, transcriptomic, and proteomic data from early-stage and chemorefractory lung
F. Skoulidis, L. Byers, L. Diao, V. Papadimitrakopoulou, P. Tong, J. Izzo, C. Behrens, H. Kadara, E. Parra, J. R. Canales, Jianjun Zhang, U. Giri, J. Gudikote, M. Cortez, Chaoxu Yang, Youhong Fan, M. Peyton, L. Girard, K. Coombes, C. Toniatti, T. Heffernan, Murim Choi, G. Frampton, V. Miller, J. Weinstein, R. Herbst, Kwok-kin Wong, Jianhua Zhang, Padmanee Sharma, G. Mills, W. Hong, J. Minna, J. Allison, A. Futreal, Jing Wang, I. Wistuba, J. Heymach   +36 more
semanticscholar   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Invasiveness Prediction of Pulmonary Adenocarcinomas Using Deep Feature Fusion Networks [PDF]

arXiv, 2019
Early diagnosis of pathological invasiveness of pulmonary adenocarcinomas using computed tomography (CT) imaging would alter the course of treatment of adenocarcinomas and subsequently improve the prognosis. Most of the existing systems use either conventional radiomics features or deep-learning features alone to predict the invasiveness. In this study,
arxiv  

Analysis of Genomic and Transcriptomic Variations as Prognostic Signature for Lung Adenocarcinoma [PDF]

, 2019
Lung cancer is the leading cause of the largest number of deaths worldwide and lung adenocarcinoma (LUAD) is the most common form of lung cancer. In this study, we carried out an integrated meta-analysis of the mutations including single-nucleotide variations (SNVs), the copy number variations (CNVs), RNA-seq and clinical data of patients with LUAD ...
arxiv   +1 more source

ADENOCARCINOMA OF RECTUM [PDF]

Annals of Surgery, 1909
n ...
openaire   +2 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Vegetating Lesions that Appear in the Scar after Neoadjuvant Therapy for Rectal Tumors: Tumor Regrowth or Benign Neoplasm?

Journal of Coloproctology
Introduction After the diagnosis of neoplasm of the middle and distal rectum, patients are often submitted to oncological treatment by neoadjuvant therapy.
Rodrigo Rezende Silva Cabral, Fernanda Biasi da Cunha, Guilherme Mattiolli Nicollelli, Maria Cristina Sartor, Antonio Sergio Brener, Wagner Carignano Winter, Ygor Degraf, Lucas Schultz Zago, Larissa Machado e Silva Gomide   +8 more
doaj   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma

Frontiers in Oncology
Patients suffering from locally advanced gastric or gastroesophageal junction adenocarcinoma often face a high postoperative recurrence rate. Despite aggressive treatment, less than 50% survive beyond five years.
Xiao Liu, Baozhen Ma, Lingdi Zhao
doaj   +1 more source